An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001 To provide access to CB7630 for patients who have completed 12 cycles of abiraterone acetate treatment and continue to receive clinical benefit from such a treatment.

• Country None
• organs None
• Specialty None

An Extended Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy and Completed Clinical Study COU-AA-003 To provide additional treatment of abiraterone acetate (CB7630) to patients who have completed 12 cycles of abiraterone acetate treatment and continue to receive clinical benefit from such treatment.

• Country None
• organs None
• Specialty None